Acromegaly Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented By Product Type (Somatostatin Analogs, Growth Hormone Receptor Antagonist (GHRA), Dopamine Agonists, Other Product Types) and Geography.

Market Snapshot

acromegaly treatment 1
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Acromegaly Treatment Market is expected to register a CAGR of 7.4% during the forecast period. Acromegaly is a hormonal disorder that develops in the pituitary gland which produces too much growth hormone during adulthood which results in an increase in bone size, including those of hands, feet, and face. Acromegaly usually affects middle-aged adults. In children, too much growth hormone can cause a condition called gigantism and may have exaggerated bone growth and an abnormal increase in height. A common sign of acromegaly is enlarged hands and feet. In adults, the tumor is the most common cause of too much growth hormone production. Some of the complications associated with the progression of acromegaly are hypertension, osteoarthritis, diabetes mellitus, goiter, and vision loss.

According to the National Institutes of Health (NIH) and Endocrine Society, estimates there are about 69,000 individuals living with acromegaly worldwide. However, symptoms of acromegaly may develop slowly, the disorder may often remain unrecognized and may, therefore, be underdiagnosed, making it difficult to determine the true frequency of acromegaly in the general population.

Furthermore, increasing incidence of pituitary tumors and acromegaly, prevalence of genetic diseases, changing lifestyle and increasing investments in R&D for developing new molecules are driving the growth of acromegaly treatment market.

Scope of the Report

As per the scope of the report, Acromegaly is a rare acquired endocrine disease that is related to excessive production of growth hormone and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations. Acromegaly Treatment Market is segmented By Product Type and Geography.

By Product Type
Somatostatin Analogs
Growth Hormone Receptor Antagonist (GHRA)
Dopamine Agonists
Other Product Types
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Somatostatin Analogs Segment is Expected to Hold a Major Market Share in the Acromegaly Treatment Market

Somatostatin analogs segment holds a significant market share in the acromegaly treatment market and is anticipated to show a similar trend over the forecast period owing to the wide availability of drugs and cost-efficiency. Somatostatin analogs have been prescribed as the first-line treatment options as these are highly effective. Some of the available marketed drugs are somavert, Signifor LAR, Sandostatin LAR, Somatuline Depot, and Parlodel. According to the National Organization for Rare Disorders, acromegaly affects males and females in equal numbers. This disorder occurs in approximately 50 to 70 people per million population worldwide. Amryt, a clinical-stage specialty pharmaceutical company focused on best-in-class treatments for orphan diseases. United States Food and Drug Administration (FDA) has granted orphan drug designation to the Company's drug compound, AP102, which has the potential to treat patients with acromegaly. Furthermore, technological advancements coupled with government support, and promising pipeline drugs are the key driving factors in the somatostatin analogs segment.

Acromegaly key trend 1.png

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global acromegaly treatment market due to the high demand for innovative products in this region. According to the National Institutes of Health (NIH) and Endocrine Society, in 13 studies of acromegaly prevalence since 1980 researchers estimate that roughly 24,000 individuals are living with acromegaly in the United States, of which an estimated 8,000 people are treated chronically with somatostatin analog injections. Furthermore, the presence of top pharma and biotech companies that are involved in the development of products for acromegaly treatment and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Acromegaly Treatment 2

Competitive Landscape

The Acromegaly Treatment Market is Consolidated competitive and consists of a few major players. Some of the prominent players operating in the acromegaly market are Pfizer Inc, Novartis AG, Validus Pharmaceuticals LLC, and Ipsen. Some of the companies involved in developing products for acromegaly are Chiasma, Inc, Crinetics Pharmaceuticals, Ionis Pharmaceuticals Inc and Midatech Pharma Plc.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence and Incidence of Acromegaly and Pituitary Tumors

      2. 4.2.2 Growing Awareness Regarding Acromegaly Disease Worldwide

      3. 4.2.3 Technological Advancements in Development of New Drugs for Acromegaly

    3. 4.3 Market Restraints

      1. 4.3.1 Complications Associated with the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product Type

      1. 5.1.1 Somatostatin Analogs

      2. 5.1.2 Growth Hormone Receptor Antagonist (GHRA)

      3. 5.1.3 Dopamine Agonists

      4. 5.1.4 Other Product Types

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Pfizer Inc

      2. 6.1.2 Novartis AG

      3. 6.1.3 Validus Pharmaceuticals LLC

      4. 6.1.4 Ipsen

      5. 6.1.5 Chiasma, Inc

      6. 6.1.6 Crinetics Pharmaceuticals

      7. 6.1.7 Ionis Pharmaceuticals Inc

      8. 6.1.8 Midatech Pharma Plc

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The undefined market is studied from 2018 - 2026.

The undefined is growing at a CAGR of 7.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Pfizer Inc, Novartis AG, Validus Pharmaceuticals LLC, Ipsen, Chiasma, Inc are the major companies operating in undefined.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!